Dianthus Therapeutics, Inc. /DE/ Earnings Per Share (Diluted)
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Earnings Per Share (Diluted) of -$0.90 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ earnings per share, diluted for the quarter ending 2026-06-30 was -$0.90.
- Dianthus Therapeutics, Inc. /DE/ earnings per share, diluted for the quarter ending 2026-03-31 was -$0.85.
- Dianthus Therapeutics, Inc. /DE/ earnings per share, diluted for the quarter ending 2025-12-31 was -$1.43.
- Dianthus Therapeutics, Inc. /DE/ earnings per share, diluted for the quarter ending 2025-09-30 was -$0.97.
- Dianthus Therapeutics, Inc. /DE/ earnings per share, diluted for fiscal 2025 was -$4.20.
- Dianthus Therapeutics, Inc. /DE/ earnings per share, diluted for fiscal 2024 was -$2.55.
- Dianthus Therapeutics, Inc. /DE/ earnings per share, diluted for fiscal 2023 was -$8.45.
- Dianthus Therapeutics, Inc. /DE/ earnings per share, diluted for fiscal 2022 was -$32.57.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.90 10-Q · filed 2026-08-04 | -$1.75 10-Q · filed 2026-08-04 | -$3.13 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$4.11 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2026-03-31 | -$0.85 10-Q · filed 2026-05-05 | -$2.26 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$3.26 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$4.17 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2025-12-31 | -$1.43 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$2.44 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$3.36 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$4.20 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | -$0.97 10-Q · filed 2025-11-05 | -$1.86 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$2.68 10-Q · filed 2025-11-05 | -$3.49 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2025-06-30 | -$0.88 10-Q · filed 2026-08-04 | -$1.71 10-Q · filed 2026-08-04 | -$2.51 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$3.25 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2025-03-31 | -$0.82 10-Q · filed 2026-05-05 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$2.37 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$2.88 derived: net income ÷ weighted average shares · filed 2026-08-04 | ||||
| 2024-12-31 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$1.54 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$2.55 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | -$0.74 10-Q · filed 2025-11-05 | -$1.25 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$1.73 10-Q · filed 2025-11-05 | -$2.46 derived: net income ÷ weighted average shares · filed 2026-04-09 | ||||
| 2024-06-30 | -$0.51 10-Q · filed 2025-08-07 | -$0.99 10-Q · filed 2025-08-07 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$2.88 derived: net income ÷ weighted average shares · filed 2026-04-09 | ||||
| 2024-03-31 | -$0.54 10-Q · filed 2025-05-12 | -$1.20 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$2.63 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$4.43 derived: net income ÷ weighted average shares · filed 2026-04-09 | ||||
| 2023-12-31 | -$0.71 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$2.69 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$5.55 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$8.45 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | -$3.78 10-Q · filed 2024-11-07 | -$10.83 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$17.40 10-Q · filed 2024-11-07 | -$26.40 derived: net income ÷ weighted average shares · filed 2024-11-07 | ||||
| 2023-06-30 | -$12.73 10-Q · filed 2024-08-08 | -$0.05 10-Q · filed 2023-08-03 | -$20.84 10-Q · filed 2024-08-08 | -$0.54 10-Q · filed 2023-08-03 | -$32.41 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$41.31 derived: net income ÷ weighted average shares · filed 2024-11-07 | ||
| 2023-03-31 | -$8.10 10-Q · filed 2024-05-09 | -$0.48 10-Q · filed 2023-05-15 | -$19.67 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$28.57 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$2.00 derived: net income ÷ weighted average shares · filed 2024-11-07 | |||
| 2022-12-31 | -$11.57 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$20.47 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$1.17 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$32.57 10-K · filed 2024-03-21 | -$1.29 10-K · filed 2023-03-23 | |||
| 2022-09-30 | -$8.90 10-Q · filed 2023-11-09 | -$0.27 10-Q · filed 2022-11-03 | -$0.45 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$21.00 10-Q · filed 2023-11-09 | -$0.95 10-Q · filed 2022-11-03 | -$2.09 derived: net income ÷ weighted average shares · filed 2023-12-21 | ||
| 2022-06-30 | -$0.29 10-Q · filed 2023-08-03 | -$0.68 10-Q · filed 2023-08-03 | -$2.12 derived: net income ÷ weighted average shares · filed 2023-12-21 | $2.29 derived: net income ÷ weighted average shares · filed 2023-12-21 | ||||
| 2022-03-31 | -$0.39 10-Q · filed 2023-05-15 | -$0.69 derived: net income ÷ weighted average shares · filed 2023-12-21 | -$1.23 derived: net income ÷ weighted average shares · filed 2023-12-21 | -$0.15 derived: net income ÷ weighted average shares · filed 2023-12-21 | ||||
| 2021-12-31 | -$0.25 derived: net income ÷ weighted average shares · filed 2023-12-21 | -$0.43 derived: net income ÷ weighted average shares · filed 2023-12-21 | -$0.29 derived: net income ÷ weighted average shares · filed 2023-12-21 | -$15.01 8-K · filed 2023-12-21 | -$1.29 10-K · filed 2022-03-08 | |||
| 2021-09-30 | -$0.30 10-Q · filed 2022-11-03 | -$0.61 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.97 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | -$0.32 10-Q · filed 2022-08-04 | -$0.67 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | -$0.36 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | -$1.71 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |